Why Early-Stage Medical Device Companies Can (and Do) Exit

When many founders of early stage Class I/II medical device companies feel stuck — out of cash, out of runway, and out of options — they can’t believe that an early exit could be an option. They mistakenly believe that the VC Mindset =  the Acquirer Mindset. While it’s true that both are ‘investors’ in your technology and share criteria that compels them to engage with you, their motivations and intentions often diverge significantly. It’s not just a little bit soul destroying to pitch your heart out, expounding on the game changing features of your medical device technology, only to endure a long series of ‘no’ or worse, no response at all. It’s understandable that you might be dejected and think:

“M&A only happens for commercially successful, late-stage devices.”

Understandable, because that’s the only kind of deal you ever hear about, but false.

While blockbuster deals grab headlines, a broad spectrum of medical device exits actually occurs across the deal size continuum — from large strategic roll-ups to lower middle-market transactions and tuck-ins that can be meaningful for those “zombie” companies that have some technology, data, or IP but no full commercialization.

Let’s break it down with some broad categories and examples.

Mega Deals — Strategic Giants & Market Makers

Deal Size: >$1 billion These are the headline makers and they do set the tone for medtech M&A activity overall.

Examples:

1. Boston Scientific → Penumbra (~$14.5B) — expanding their cardiovascular portfolio to drive revenue scale and strategic breadth. 
2. Johnson & Johnson → Shockwave Medical (~$13.1B) — a high-growth cardiovascular solution added to J&J’s medtech arsenal. 
3. Abbott → Exact Sciences (~$21B) and Blackstone/TPG → Hologic (~$18.3B) — multi-billion strategic plays reshaping device and diagnostics segments. 

The upshot: Mega deals shape the narrative and signal where growth categories are but they are far from the only path for exits.

Middle Market Deals — Established Assets & Strategic Growth

Deal Size: ~$200M–$1B+ These include acquisitions of solid, revenue-generating companies that bring differentiated technology, complement portfolios, and have a strong customer base

Examples from past medtech activity:

1. SeaSpine’s acquisition of 7D Surgical (~$110M) — navigation tech that enhanced minimally invasive surgery capabilities. 
2. Smith+Nephew acquisitions in the low-hundreds of millions — e.g., $240M deal to bolster extremity orthopedics. 
3. NuVasive → Simplify Medical (~$150M+) — strategic targeted addition of a differentiated disc replacement platform. 

The upshot: These are medtech exits with substantive enterprise value yet they’re far below “mega” headline figures, and are significant for their founders and investors.

Lower Middle Market Deals — Legitimate M&A for Early Stage

Deal Size: ~$2M–$50M (sometimes up to ~$100M) In M&A terminology, this category is typically called the lower middle market (LMM) — welcome to the exit zone for early stage and development-stage companies that are not yet commercially dominant or viable. These deals may involve:

1. Asset or portfolio acquisitions, where a larger player buys technology/IP without all commercial assets.
2. Roll-ups and tuck-ins where a smaller device or tool fills a strategic gap.
3. Milestone-based deals that include up-front payment + earn-outs (this is the norm).

Illustrative examples:

Bioness acquired by Bioventus (~$45M upfront + potential milestones) — a small but strategically fitting technology asset.

NuGEN Technologies acquired by Tecan (~$54M) — a smaller medtech-adjacent deal with a niche device component.

Hansa Medical acquired (~$40M) — small company acquisition flagged in broader transaction lists.

Note: Many lower middle market medtech deals never become public headlines because they’re below the threshold for material reporting for public companies or private acquirers opt not to disclose for a variety of reasons. They might be asset sales, technology buys, or IP acquisitions — but they are real M&A outcomes.

Micro & Strategic Tuck-Ins — Opportunistic Exits

Deal Size: <$10M–$25M These smaller transactions often fly under the radar because they are:

1. Undisclosed privately
2. Often bootstrapped or ‘friends, family, and fools’ funded 
3. Focused on specific IP modules, regulatory filings, or niche products

Examples from industry transaction listings include:

1. Medtronic → Laser Associated Sciences ($ undisclosed), part of tuck-in cluster - Small innovation‑driven deal to add a single functional capability (distal blood flow monitoring) into Medtronic’s vascular/peripheral portfolio.
2. Medtronic → Stimgenics ($ undisclosed), part of tuck-in cluster - Waveform/IP acquisition complementary to existing implantable stimulators; typical IP‑heavy micro‑exit aligned with therapy refinement
3. Vyaire Medical → Revolutionary Medical Devices (RMD) (likely <$25M) - Respiratory strategic acquiring a single‑product airway‑management startup; classic micro‑exit with tech fitting tightly into acquirer’s portfolio

Upshot: As with LMM transactions, these deals are often undisclosed and integrated quietly into a bigger player’s R&D pipeline; but they represent legitimate exits for companies with technology and some validation and are statutory M&A.

Why This Matters for Early Stage Founders

Many early stage, non-commercial (or very early commercial) medtech companies do have viable exit paths — including:

✔ Strategic tuck-ins

✔ Technology/IP sales

✔ Milestone-based small M&A

✔ Divestitures to larger platforms for further development or commercialization

These outcomes may not make headlines, but they are legitimate, valuable, and meaningful exits — especially for companies that have built something compelling, even without full commercialization.

Reframing the ‘VC Rejection’ and ‘Too Small to Matter’ Mindset

Instead of thinking:

“M&A is only an option for commercially successful medical devices” 

Try this:

“M&A exists along a spectrum — and many exits, especially in medtech, happen through strategically aligned deals that don’t need to be billion-dollar valuations to deliver value.”

And, instead of thinking:

“All the VCs rejected us so we must have no value”

Try this:

“VCs have a set of criteria that serves both their fund ethos and their obligations to their LPs. Our current assets and anticipated value don’t match their requirements but for strategic acquirers, our IP, technology, or market favor may be exactly what they need to fulfill their corporate priorities. ”